Cipla Ltd

Cipla Limited reported Q2 FY27 revenue of INR7,404 crores, reflecting 4% sequential growth, driven by strong performance across its businesses. One India achieved 12% Y-o-Y growth, with branded prescription business growing 15%, led by chronic therapies such as respiratory (11%), antidiabetes (50%), urology (11%), and dermatology (16%). The company highlighted successful launches, including Revesmart, Galvus DM, and SR, and secured approvals for generic Ventolin and Advair in the U.S. North America revenue reached $172 million, with Cipla maintaining a 22% market share in U.S. Albuterol MDI. Strategic partnerships, such as with Qilu for Pembrolizumab biosimilar and CTTQ for HER2 bispecific ADC, were emphasized. Financially, EBITDA margin improved to 18.7%, with gross margin at 64.4%. R&D investment stood at 5.7% of revenue, with guidance for 6-7% for the year. The company aims to achieve a $1 billion annualized revenue run rate in North America by year-end, supported by upcoming product launches. Management noted challenges in the U.S. FDA inspections but emphasized commitment to compliance. The consumer health segment showed strong growth, and emerging markets like South Africa and EMEU demonstrated resilience. The company remains focused on innovation, pipeline expansion, and maintaining growth in core businesses.

The document highlights strong revenue growth, successful product launches, strategic partnerships, and improved financial metrics, indicating a positive outlook.